Skip to main content

Table 3 Comparison of the results between the overall meta-analysis for THA/HA and the THA-subgroup

From: Comparison of short-term outcomes between SuperPATH approach and conventional approaches in hip replacement: a systematic review and meta-analysis of randomized controlled trials

 

THA/HA

THA

Pts; RCTs, n

Results

Pts; RCTs, n

Results

Operation time

630; 10 [22–27, 29–32]

MD = 18.40, 95% CI 5.38 to 31.42, I2 = 98%, p = 0.01

398; 6 [22–25, 30, 32]

MD = 13.79, 95% CI − 6.47 to 34.05, I2 = 96%, p = 0.14

Incision length

552; 8 [22–25, 27, 30–32]

MD = − 4.84, 95% CI − 7.04 to − 2.64, I2 = 99%, p < 0.01

398; 6 [22–25, 30, 32]

MD = − 5.47, 95% CI − 8.34 to − 2.60, I2 = 99%, p < 0.01

Intraoperative blood loss

568; 9 [22–27, 29, 30, 32]

MD = − 29.84, 95% CI − 133.69 to 74.02, I2 = 99%, p = 0.53

398; 6 [22–25, 30, 32]

MD = − 20.18, 95% CI − 128.21 to 168.57, I2 = 99%, p = 0.74

Postoperative drainage volume

370; 4 [25, 27, 29, 32]

MD = − 75.16, 95% CI − 200.22 to 49.90, I2 = 100%, p = 0.15

238; 2 [25, 32]

MD = − 15.25, 95% CI − 43.11 to 12.61, I2 = 0%, p = 0.09

Pain VAS 1 day p/o

222; 4 [22, 24, 30, 32]

MD = − 0.89, 95% CI − 2.96 to 1.19, I2 = 85%, p = 0.27

222; 4 [22, 24, 30, 32]

MD = − 0.89, 95% CI − 2.96 to 1.19, I2 = 85%, p = 0.27

Pain VAS 3 days p/o

222;4 [22, 24, 30, 32]

MD = − 1.11, 95% CI − 2.35 to 0.13, I2 = 75%, p = 0.06

222; 4 [22, 24, 30, 32]

MD = − 1.11, 95% CI − 2.35 to 0.13, I2 = 75%, p = 0.06

Pain VAS 7 days p/o

348; 4 [23, 30–32]

MD = − 1.39, 95% CI − 2.57 to − 0.21, I2 = 87%, p = 0.03

286; 3 [23, 30, 32]

MD = − 1.15, 95% CI − 2.68 to 0.38, I2 = 86%, p = 0.08

Pain VAS 3 months p/o

182; 4 [22–24, 31]

MD = − 0.10, 95% CI − 0.85 to 0.65, I2 = 61%, p = 0.70

120; 3; 182; 4 [22–24]

MD = 0.02, 95% CI − 1.37 to 1.42, I2 = 74%, p = 0.95

Pain VAS 12 months p/o

120; 3 [22–24]

MD = − 0.09, 95% CI − 0.32 to 0.13, I2 = 0%, p = 0.22

120; 3 [22–24]

MD = − 0.09, 95% CI − 0.32 to 0.13, I2 = 0%, p = 0.22

Hospitalization period

242; 4 [22, 23, 27, 28]

MD = − 2.80, 95% CI − 6.61 to 1.02, I2 = 96%, p = 0.10

150; 3 [22, 23, 28]

MD = − 1.97, 95% CI − 7.49 to 3.56, I2 = 93%, p = 0.27

HHS 7 days p/o

246; 4 [23, 26, 28, 31]

MD = 10.24, 95% CI 0.27 to 20.21, I2 = 96%, p = 0.05

146; 2 [23, 28]

MD = 5.40, 95% CI − 5.82 to 16.62, I2 = 7%, p = 0.10

HHS 14 days p/o

112; 3 [22–24]

MD = − 1.88, 95% CI − 24.88 to 21.13, I2 = 73%, p = 0.76

112; 3 [22–24]

MD = − 1.88, 95% CI − 24.88 to 21.13, I2 = 73%, p = 0.76

HHS 1 month p/o

214; 3 [23, 25, 26]

MD = 4.49, 95% CI − 2.96 to 11.94, I2 = 93%, p = 0.12

176; 2 [23, 25]

MD = 3.12, 95% CI − 14.84 to 21.08, I2 = 94%, p = 0.27

HHS 3 months p/o

516; 8 [22–25, 28, 31–33]

MD = 1.64, 95% CI − 2.91 to 6.19, I2 = 95%, p = 0.42

454; 7 [22–25, 28, 32, 33]

MD = 1.02, 95% CI − 4.18 to 6.23, I2 = 95%, p = 0.65

HHS 6 months p/o

382; 6 [22, 24, 25, 28, 31, 32]

MD = 0.63, 95% CI 0.11 to 1.15, I2 = 0%, p = 0.03

320; 5 [22, 24, 25, 28, 32]

MD = 0.65, 95% CI − 0.07 to 1.36, I2 = 0%, p = 0.07

HHS 12 months p/o

174; 4 [22–24, 28]

MD = 0.64, 95% CI − 0.36 to 1.64, I2 = 0%, p = 0.13

174; 4 [22–24, 28]

MD = 0.64, 95% CI − 0.36 to 1.64, I2 = 0%, p = 0.13

Cup anteversion angle

160; 4 [22–24, 30]

MD = − 0.62, 95% CI − 1.51 to 0.28, I2 = 11%, p = 0.12

160; 4 [22–24, 30]

MD = − 0.62, 95% CI − 1.51 to 0.28, I2 = 11%, p = 0.12

Cup abduction angle

160; 4 [22–24, 30]

MD = − 1.20, 95% CI − 2.79 to 0.40, I2 = 0%, p = 0.10

160; 4 [22–24, 30]

MD = − 1.20, 95% CI − 2.79 to 0.40, I2 = 0%, p = 0.10

Postoperative complications

407; 6 [24, 26, 27, 29, 30, 32]

OR = 0.83, 95% CI 0.12 to 5.98, I2 = 37%, p = 0.81

237; 3

OR = 2.37, 95% CI 0.03 to 206.84, I2 = 20%, p = 0.49

  1. THA total hip arthroplasty, HA hemiarthroplasty, Pts patients